Inotek Pharmaceuticals Corporation is a clinical-stage, drug development company, founded in 1996. The Company has built a robust small molecule chemistry expertise, leading to five distinct programs focused on DNA repair, cell necrosis and critical inflammatory pathways associated with tissue injury. Inotek is a leader in �PARP inhibitors�, and the Company is exploiting this target to develop therapeutics for a broad array of clinical applications.